Blog
RSS FeedPosted by Michael Wonder on 11 Jul 2016
Uncertainty for Masterton mother after drug trial ditched
11 July 2016 - Masterton mother of three Allyson Lock is one of 11 Kiwis with Pompe disease, a rare and ...
Posted by Michael Wonder on 07 Jul 2016
Proposal to award sole supply to goserelin acetate (Zoladex) and reference price leuprorelin acetate (Eligard and Lucrin PDS)
7 July 2016 - PHARMAC has entered into a provisional agreement with AstraZeneca. ...
Posted by Michael Wonder on 05 Jul 2016
New Zealand public help improve PHARMAC decision making
6 July 2016 - After listening to what New Zealanders had to say, PHARMAC has changed the way it makes decisions ...
Posted by Michael Wonder on 05 Jul 2016
Factors for consideration
30 June 2016 - The factors for consideration are the framework PHARMAC uses when making funding decisions. ...
Posted by Michael Wonder on 05 Jul 2016
Devices savings to help hospitals manage budgets
5 July 2016 - New data from PHARMAC is predicting DHB hospital spending on surgical and medical devices will fall by ...
Posted by Michael Wonder on 30 Jun 2016
New Zealand Pharmaceutical Schedule - 1 July 2016 update
1 July 2016 - The beginning of a new financial year sees the listing of some new medicines. ...
Posted by Michael Wonder on 30 Jun 2016
PHARMAC's credibility questioned by Labour
29 June 2016 - The acceptance of Keytruda's effectiveness after PHARMAC's budget was boosted undermines the medicines funding agency's credibility, Labour ...
Posted by Michael Wonder on 29 Jun 2016
Consultation open on pembrolizumab funding
29 June 2016 - PHARMAC has commenced consultation on a proposal to fund pembrolizumab (Keytruda) from 1 September 2016. If funded, ...
Posted by Michael Wonder on 28 Jun 2016
Cancer patients get another option with PHARMAC eyeing funding for Keytruda
28 June 2016 - Melanoma patients are likely to get a second drug treatment option under a new proposal to provide ...
Posted by Michael Wonder on 28 Jun 2016
Proposal relating to pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
28 June 2016 - PHARMAC recently announced a decision to fund nivolumab (Opdivo) for patients with unresectable or metastatic (stage III ...
Posted by Michael Wonder on 28 Jun 2016
Proposal to list cholic acid (Cholebiol) for rare disorder
28 June 2016 - PHARMAC is seeking feedback on a proposal to list cholic acid (Cholebiol) resulting from a provisional agreement ...
Posted by Michael Wonder on 27 Jun 2016
Proposal for sole subsidised supply of progestogen-only long-acting intra-uterine system (Mirena)
27 June 2016 - Following a request for proposals for the supply of a long-acting intra-uterine progestagen, PHARMAC is seeking feedback ...
Posted by Michael Wonder on 24 Jun 2016
Enoxaparin sodium and plerixafor proposal
24 June 2016 - PHARMAC is seeking feedback on a proposal involving enoxaparin sodium and plerixafor, resulting from a provisional agreement ...
Posted by Michael Wonder on 23 Jun 2016
Agreement with Biotronik Australia for the supply of interventional cardiology devices
23 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Biotronik Australia Pty Limited for the ...
Posted by Michael Wonder on 21 Jun 2016
Agreement with Smith & Nephew for the supply of orthopaedic trauma implants
21 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Smith and Nephew for the supply ...